• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Biotechnology’s Role in Improving Stroke Outcomes

    CEO Spotlight: Marc Kikuchi

    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Novavax Submits EUA for Protein-based COVID-19 Vax Booster

    BeiGene, Ontada Enter Strategic Oncology Alliance

    AskBio Appoints Clinical Ops Executives

    SpectrumX Partners With UK Contract Manufacturer

    GL Chemtec Partners with Edgewater Capital to Accelerate Growth
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    SpectrumX Partners With UK Contract Manufacturer

    Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership

    Almac Invests $65M to Expand North American HQ

    Captor Therapeutics Selects CDMO for Clinical Trial Materials

    Catalent to Acquire Metrics Contract Services for $475M
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    UPS to Acquire Healthcare Logistics Provider Bomi Group

    Marken to Acquire Medical Courier Business of Cedra Express

    5 Key Features of Agile Pharmaceutical Packaging Supply Chains That Drive Results

    Novavax Expands Manufacturing Agreement with SK bioscience

    Lonza Continues to Lead the Market with Innovative Hard Empty Capsules
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Novavax Submits EUA for Protein-based COVID-19 Vax Booster

    GL Chemtec Partners with Edgewater Capital to Accelerate Growth

    West Pharmaceutical Makes Strategic Investment in Latch Medical

    “3 Key Trends” with James Park

    Captor Therapeutics Selects CDMO for Clinical Trial Materials
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Chime Biologics Receives Commercial Manufacturing License

    Automation Is Key to Meeting Demands in Pharmacovigilance

    UBC Acquires Examoto

    Responding to Consumer Complaints While Working with CMOs

    WuXi Vaccines Receives GMP Certificate from HPRA
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    CMC Pharmaceuticals

    Baxter BioPharma Solutions

    Quotient Sciences

    Societal CDMO

    Kyongbo Pharmaceutical
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    CMC Pharmaceuticals

    Baxter BioPharma Solutions

    Quotient Sciences

    Societal CDMO

    Kyongbo Pharmaceutical
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Solid Dose Manufacturing: It’s Time to Trade-in Your 1952 Studebaker

    Making a solid case for PAT, QbD and continuous manufacturing in the pharma industry

    Solid Dose Manufacturing: It’s Time to Trade-in Your 1952 Studebaker
    Related CONTENT
    • Asymchem
    • Mogene
    • Reed-Lane
    • Vetio Animal Health
    • Contracting And Outsourcing Agenda
    Emil W. Ciurczak, DoraMaxx Consulting03.06.19
    Not to sound too “Twilight Zone,” but I would like to begin with…cue the background music:

    “Picture if you will, a manufacturer of pharmaceutical poultices. As his equipment wears out, he chooses to replace it with the same units. He consciously replaces his equipment with essentially the same ones he has used since 1960. Prepare to enter…The Same-Old, Same-Old Zone.”

    The question one must immediately ask is “why?”

    When queried, the nervous man will stammer, “B-b-b-b-but the mean old QA man won’t let me change.” Or, “The mean old FDA (EMA – you pick one) doesn’t like change.” Or, and this is really the reason, “My people are familiar with model XYZ from Supplier ABC, so why change?”

    Hence, when some pain-in-the-neck column writer suggests that a contract manufacturing organization (CMO) move into the light and try PAT, QbD, and, ta-da, continuous manufacturing, we hear a chorus of reasons why they can’t. Never underestimate the power of the Dark Side.

    In previous columns, I have made the case for the economies of PAT/QbD, at least as far as attracting partners who are already using PAT for their blockbuster products in their own facilities. And, how process analyses can save time and money as well as attract new business. Expanding on this concept, I need to examine some truisms and observations:
    1. All equipment wears out and becomes un-fixable. The third law of thermodynamics, loosely stated, is “Entropy, like Karma, is b---h.” All units will need to be replaced, at some point; some earlier than later.
    2. Actually, very few equipment manufacturers either continue making the same models or have replacement parts for them indefinitely. Try finding an engine part for a 1971 Ford Pinto; worse yet, a 1972 Maverick.
    3. The trends in modern process equipment are larger and faster. That means that classic batch processing formulation will need to be updated every time a larger mixer or faster tablet press is added to the line.
    4. Classic formulation is seldom based on first principles or PAT or QbD. In all too many cases, scale-up may be described as hunt-and-peck. Doubling the size of a blender, for example, does not mean simply doubling the time for mixing. Without PAT-based materials’ knowledge, numerous test runs need to be made to make the new hardware produce a similar blend to the old unit. Plus, without in-line measuring technology, the new process would need to be stopped, have samples taken, have the samples analyzed in a lab, and only then can a new mixing SOP be written.
    5. There is the capacity conundrum: if you stay small, you will need to turn down business, which hurts future contracts; if you expand with current batch-process equipment and do not increase business enough to fully utilize the equipment and personnel, you will squander the profits of the smaller contracts you now have.
    6. Your clients are being squeezed for lower prices, so you will, in turn, be squeezed to lower production costs. So, increasing size, which has a number of hidden costs, can be a two-edged sword: both capacity AND overhead increase. Much like the addiction-spiral of blockbuster drugs, the success of selling more spurs you on to building for a larger capacity which, in turn, necessitates selling more product, and so on.
    Now, I have always told my groups, it’s better to have too much work than not enough to keep your jobs. The trick in this case is that we do not have to choose between two options because there is a third: think small! After the inflation of Big Pharma by M&A for several decades, these companies are beginning to shrink. There is no one reason for this, but there is a perfect storm of conditions that are encouraging downsizing:
    1. After a planned program of cross-validation, companies are able to produce whichever product they need at a multitude of sites. No longer do they need to have specialized plants for each blockbuster or “normal” product. This allows them to have fewer footprints, saving many millions of dollars, Euros, pounds, etc. each year. With the biggest-selling names coming off patent, this versatility is needed.
    2. When the inevitable downsizing occurs, there is money to be made from divesting the equipment and properties of the unneeded plants. This is now the seed money for modernizing the remaining plants.
    3. Even with the cost savings on brick and mortar and personnel, there can be loss of opportunity in off-patent, personalized meds, and orphan drugs, each of which takes up production bandwidth.
    All these facts are all well and good, but what do they have to do with contract manufacturers? Well, let’s see. The industry has fewer sites, yet potentially more lots—albeit smaller lots—to produce. That means, using conventional old-time GMP batch-type processing equipment, even though the amount of product sold may be less and the profit margin slimmer, the work involved and warehouse space needed may not be significantly lowered. Why?
    1. The cleaning of each piece and subsequent cleaning validation still takes approximately the same time. A thousand batches of any drug product, no matter how large the yield, will take pretty much as long.
    2. If the over-flow or specialty products are contracted to CMOs while still being produced in the traditional manner, then they will suffer the same log-jam of too many products for too few process lines.
    3. When a manufacturer makes a large number of different products, the logistics of quarantine and analysis of many more APIs more than makes up for the shorter run times of each individual lot.
    So, despite a lower income flow, now we have potentially more numbers of lots and, even though smaller than during the heydays of their patent protection, the work involved remains nearly the same. Not the path to prosperity. Quite succinctly, replacing worn or broken equipment with like models does nothing to alleviate the blockage, save money, nor increase profits.

    Since the FDA released the PAT Guidance (2004) and subsequent documents (ICH Q9-13), the industry in the U.S. and Europe has slowly been moving towards process monitoring (PAT) and Quality by Design (QbD). The former paradigm gives us the data needed to assure proper mixing, drying, and so forth, while the second is using the PAT-generated data to manufacture reproducible and quality products.

    This is all well and good. The end product of a properly designed QbD program is, indeed, an excellent and reproducible product and no out-of-specification (OOS) batches. However, while the quality of the product may improve, simply making better batches doesn’t mean making more or faster batches. So, while employing PAT/QbD is a great idea, continuing to use conventional processing only give at best a 10-15% savings in time, which, in turn, barely makes a dent in the throughput crunch. What is needed is a different, 21st century solution.

    A number of larger Pharma companies have bought into the idea of continuous manufacturing (CM) for several reasons:
    1. A smaller footprint is, in itself, a cost savings.
    2. Several of the companies have found that the contiguous units can be cleaned in-place. The conventional solvents, soap and water, followed by copious rinses and drying, then waiting for lab results keeps instruments out of use for large percentages of the available workday.
    3. Scale-up times are avoided. When the small, experimental or clinical batch size is shown to be suitable for sale after NDA or ANDA approval, the exact same equipment is used for retail batches. They just run longer to produce more tablets or capsules.
    4. Site validation becomes infinitely simpler. Pfizer has even gone so far as to produce a CM suite at a central location, validate it for use, then, via a tractor trailer, drive it to another site for use. The entire system need only be shown to produce the same product as when first assembled and, since it was never dissembled, can be put into use far sooner than previously for site validations.
    5. Cost of scale needs to be considered. If most CM units are similar, then spare parts, maintenance, and training can be uniform. Since all the units will have nearly the same footprint, buildings will also be uniform. This, too, will lead to savings of building costs. You can use the same blueprints, if not the same construction firms.
    So, with the spate of drugs becoming generic, specialty drugs (3-D printed, etc.), shrinking floor space of larger companies, and the increase of demand due in large part to aging populations, we have what may be referred to as an insurmountable opportunity. What is actually needed is for upper management to grow a spine. They simply need to ignore nay-sayers who are afraid to leave the mid-20th century and go for it.

    Much as I like my uncle’s Studebaker, I drive a new Ford Fusion: spare parts are in abundance.


    Emil W. Ciurczak
    DoraMaxx Consulting

    Emil W. Ciurczak has worked in the pharmaceutical industry since 1970 for companies that include Ciba-Geigy, Sandoz, Berlex, Merck, and Purdue Pharma, where he specialized in performing method development on most types of analytical equipment. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies (PAT) in drug manufacturing and development.
    Related Searches
    • it
    • Capsules
    • Development
    • Pharma
    Suggested For You
    Asymchem Asymchem
    Mogene Mogene
    Reed-Lane Reed-Lane
    Vetio Animal Health Vetio Animal Health
    Contracting And Outsourcing Agenda Contracting And Outsourcing Agenda
    Are We Embracing FDA’s Messages? Are We Embracing FDA’s Messages?
    Gliknik Receives $15M Milestone from Pfizer Gliknik Receives $15M Milestone from Pfizer
    CDMOs On The Rise CDMOs On The Rise
    Aphena Ready for Opioid Crisis Response Act Aphena Ready for Opioid Crisis Response Act
    Akorn Receives FDA Warning Letter Akorn Receives FDA Warning Letter
    Pfizer, GSK Form Consumer Healthcare JV Pfizer, GSK Form Consumer Healthcare JV
    Aileron, Pfizer in Clinical Collaboration Aileron, Pfizer in Clinical Collaboration
    The Great Diaspora of the Pharma Industry The Great Diaspora of the Pharma Industry
    Pharma Tech Industries Hires Senior QC Professionals Pharma Tech Industries Hires Senior QC Professionals
    Janssen Receives FDA Approval for INVOKANA Janssen Receives FDA Approval for INVOKANA

    Related Buyers Guide Companies

    • Asymchem

      Asymchem

      ...
      Mandy Boyd, Asymchem 12.01.20

    • Mogene

      ...
      Craig Morley, CEO 11.17.20

    • Serialization | Vials
      Reed-Lane

      Reed-Lane

      Reed-Lane is a privately owned contract packager located in northern New Jersey that has been serving the pharmaceutical market for over 60 years.
      Joe Luke, VP Sales & Marketing 10.25.19


    • Vetio Animal Health

      Vetio Animal Health

      ...
      John Kane, CEO 10.24.19

    • Contracting And Outsourcing Agenda

      ...
      09.17.19

    Loading, Please Wait..
    Trending
    • Thermo Fisher Expands NY Cell Culture Media Manufacturing Site
    • Pfizer, Neurocrine Terminate Collaboration
    • Almac Invests $65M To Expand North American HQ
    • Catalent To Acquire Metrics Contract Services For $475M
    • Novavax Submits EUA For Protein-based COVID-19 Vax Booster
    Breaking News
    • Novavax Submits EUA for Protein-based COVID-19 Vax Booster
    • BeiGene, Ontada Enter Strategic Oncology Alliance
    • AskBio Appoints Clinical Ops Executives
    • GL Chemtec Partners with Edgewater Capital to Accelerate Growth
    • SpectrumX Partners With UK Contract Manufacturer
    View Breaking News >
    CURRENT ISSUE

    July/August 2022

    • Biotechnology’s Role in Improving Stroke Outcomes
    • CEO Spotlight: Marc Kikuchi
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Charlotte’s Web Sports Product Line to Undergo NSF Certification Process
    ADM and Benson Hill Partner to Scale High Protein Soy for U.S. Market
    Tazo Transitions to Regenerative Organic Agriculture
    Coatings World

    Latest Breaking News From Coatings World

    What are you Reading this Week?
    SONGWON Industrial Group Reports Strong Q2 Financial Results
    PPG Completes COLORFUL COMMUNITIES Project for Boys & Girls Clubs of Greater Houston
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Spartech Promotes Three Staff Members
    Elisabeth Lackner Named Chief Scientific Officer at Element Materials Technology
    Natech Plastics Purchases Three New Injection Molding Machines
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Novavax Submits EUA for Protein-based COVID-19 Vax Booster
    BeiGene, Ontada Enter Strategic Oncology Alliance
    AskBio Appoints Clinical Ops Executives
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Body Shop Encourages Young People to Vote
    Weekly Recap: Howard Kaneff Dies, Keys Soulcare Adds SPF Skincare Offering & More
    Arkay Chairman Emeritus Howard Kaneff Has Died
    Happi

    Latest Breaking News From Happi

    In-Cosmetics Asia Returns to Bangkok to Deliver Look at Market Trends and Ingredient Innovations
    Perfect Corp. AI Skin Analysis Beauty SaaS Brand Console is Now HIPAA-Compliant
    Black-Owned Dinobi Detergent Uses Plant-Based Green Ingredients
    Ink World

    Latest Breaking News From Ink World

    Weekly Recap: Printing Ink Primer, Zeller+Gmelin Lead This Week’s News Stories
    Heidelberg Enjoys Successful Start to 2022-23 Fiscal Year
    Mimaki Announces New LATAM Website
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Pro Label Inc. installs first Mark Andy DSiQ hybrid press
    Gallus launches Gallus One inkjet label press
    Esko, Constantia Flexibles announce acquisitions and more
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Daio Paper Acquires Pet Care Products Manufacturer
    Honest Reports Increased Revenue
    Weekly Recap: Essity Switches to Recyclable Packs for Feminine Pads, FTC Sues PPE Maker on False Origin Claims & More
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Bioventus Achieves Strong Growth in Q2 2022
    Bone Void Fillers Market Growing at 6%
    ODT's Most-Read Stories This Week—Aug. 13
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: ALTANA, Universal Display and Emerson Top This Week’s Stories
    eMagin Corporation Announces 2Q 2022 Results
    Zebra Technologies’ Emission Reduction Targets Validated by SBTi

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login